Metformin for the management of tuberous sclerosis: What does the evidence tell us?
作者信息
Srinivasan Anirudh, Naga Shashi Kiran Beti, Koduvath Abdulla, Pal Auroprakash, Suresh Ananthu, Kannan Amudhan, Ravichandran Mirunalini
机构信息
Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
出版信息
EXCLI J. 2021 Sep 27;20:1474-1475. doi: 10.17179/excli2021-4213. eCollection 2021.
Abstract
摘要
相似文献
1
Metformin for the management of tuberous sclerosis: What does the evidence tell us?
EXCLI J. 2021 Sep 27;20:1474-1475. doi: 10.17179/excli2021-4213. eCollection 2021.
2
Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.
Pediatr Neurol. 2013 Oct;49(4):255-65. doi: 10.1016/j.pediatrneurol.2013.08.002.
3
Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC).
PLoS One. 2012;7(2):e31900. doi: 10.1371/journal.pone.0031900. Epub 2012 Feb 21.
4
Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist.
Pediatr Neurol. 2015 Jan;52(1):25-35. doi: 10.1016/j.pediatrneurol.2014.10.004. Epub 2014 Oct 16.
5
Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Pediatr Neurol. 2015 Mar;52(3):281-9. doi: 10.1016/j.pediatrneurol.2014.10.028. Epub 2014 Nov 20.
6
Current management for epilepsy in tuberous sclerosis complex.
Curr Opin Neurol. 2006 Apr;19(2):119-23. doi: 10.1097/01.wco.0000218225.50807.12.
7
Management of Self-Injurious Behavior, Aggression, and Psychogenic Non-Epileptic Seizures in Patients With Tuberous Sclerosis: A Case Report With a Review of Literature.
Cureus. 2020 Nov 26;12(11):e11715. doi: 10.7759/cureus.11715.
8
Everolimus for cardiac rhabdomyomas in children with tuberous sclerosis. The ORACLE study protocol (everOlimus for caRdiac rhAbdomyomas in tuberous sCLErosis): a randomised, multicentre, placebo-controlled, double-blind phase II trial.
Cardiol Young. 2020 Mar;30(3):337-345. doi: 10.1017/S1047951119003147. Epub 2020 Jan 27.
9
10
Tuberous sclerosis complex.
Curr Opin Neurol. 2000 Apr;13(2):115-9. doi: 10.1097/00019052-200004000-00001.
引用本文的文献
1
Subependymal Giant Cell Astrocytoma: The Molecular Landscape and Treatment Advances.
Cancers (Basel). 2024 Oct 7;16(19):3406. doi: 10.3390/cancers16193406.
2
Tuberous Sclerosis, Type II Diabetes Mellitus and the PI3K/AKT/mTOR Signaling Pathways-Case Report and Literature Review.
Genes (Basel). 2023 Feb 8;14(2):433. doi: 10.3390/genes14020433.
本文引用的文献
1
The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial.
EClinicalMedicine. 2021 Jan 14;32:100715. doi: 10.1016/j.eclinm.2020.100715. eCollection 2021 Feb.
2
The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth.
Br J Clin Pharmacol. 2019 Jan;85(1):37-46. doi: 10.1111/bcp.13780. Epub 2018 Nov 8.
3
mTOR Inhibitors in Tuberous Sclerosis Complex.
Curr Neuropharmacol. 2012 Dec;10(4):404-15. doi: 10.2174/157015912804143595.
4
Tuberous sclerosis complex: a review of the management of epilepsy with emphasis on surgical aspects.
Childs Nerv Syst. 2006 Aug;22(8):896-908. doi: 10.1007/s00381-006-0130-7. Epub 2006 Jun 13.
5
Managing epilepsy in tuberous sclerosis complex.
J Child Neurol. 2004 Sep;19(9):680-6. doi: 10.1177/08830738040190090801.
6
Non-penetrance in tuberous sclerosis.
Lancet. 2000 May 13;355(9216):1698. doi: 10.1016/s0140-6736(00)02247-9.
Zotero 插件